- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01689389
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Argenteuil Cedex, Francia
- Research Site
-
Belley, Francia
- Research Site
-
Castelmaurou, Francia
- Research Site
-
Cavaillon, Francia
- Reserach Site
-
Les Mureaux, Francia
- Research Site
-
Lille, Francia
- Research Site
-
Marseille, Francia
- Research Site
-
Montpellier, Francia
- Research Site
-
Nimes Cedex, Francia
- Research Site
-
Obernai, Francia
- Research Site
-
Paris, Francia
- Research Site
-
Rennes, Francia
- Research Site
-
Saintes Cedex, Francia
- Research Site
-
Sens, Francia
- Research Site
-
St Dizier, Francia
- Research Site
-
St Egreve Cedex, Francia
- Research Site
-
Toulouse, Francia
- Research Site
-
Tours, Francia
- Research Site
-
Ussel Cedex, Francia
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- New patients treated with Xeroquel XR
- Patients aged 18 years and over
- Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria
Exclusion Criteria:
- Patient included in a therapeutic trial (Huriet-Serusclat Act)
- Patient refusing to participate in the study
- Pregnant women
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Main study population
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months. |
Schizophrenia SoC sample
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
|
Bipolar SoC sample
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Descriptive analysis of variables related with how the drug is prescribed and used by the patient.
Lasso di tempo: At inclusion
|
Variables related with how the drug is prescribed and used by the patient [doses in mg/day, titration (yes/no), time of administration (morning/middle of the day/afternoon/evening), concomitant treatments] are going to be described.
|
At inclusion
|
Description of patient's socio-demographics profile.
Lasso di tempo: At inclusion
|
Age, gender, educational and professional status, co-habitation are going to be described.
|
At inclusion
|
Descriptive analysis of medical history.
Lasso di tempo: At inclusion
|
Diagnosis, family history of psychiatric disorders, number of suicidal attempts within the last 12 months, co-morbidities, treatments received during the last 12 months, laboratory and exam data will be included in the description.
|
At inclusion
|
Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S).
Lasso di tempo: At inclusion
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
At inclusion
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in Clinical Global Impressions Scale - Severity (CGI-S) during the treatment.
Lasso di tempo: From baseline to 12 months
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
From baseline to 12 months
|
Quetiapine XR and concomitant treatment stop, stop date, reasons to stop, restart, restart date, reasons to restart.
Lasso di tempo: From baseline to 12 months
|
From baseline to 12 months
|
|
Descriptive analysis of the treatment changes: drug switches.
Lasso di tempo: From baseline to 12 months
|
From baseline to 12 months
|
|
Description of patterns of healthcare management resource use related with psychiatric disorders under investigation.
Lasso di tempo: From baseline to 12 months
|
From baseline to 12 months
|
|
Change in Body Mass Index (BMI).
Lasso di tempo: From baseline to 12 months
|
From baseline to 12 months
|
|
Laboratory tests- cholesterol.
Lasso di tempo: From baseline to 12 months
|
Blood test- cholesterol.
|
From baseline to 12 months
|
Descriptive analysis of all adverse events.
Lasso di tempo: From baseline to 12 months
|
From baseline to 12 months
|
|
Relapses (only for the schizophrenia subpopulation).
Lasso di tempo: From baseline to 12 months
|
New psychiatric hospitalisation, deterioration of the CGI-S (Clinical Global Impressions Scale - Severity) by at least 3 points for a baseline score of 1, at least 2 points for a baseline score of 2 or 3, at least 1 point for a baseline score of 4.
|
From baseline to 12 months
|
Laboratory tests- glycemia.
Lasso di tempo: From baseline to 12 months
|
Blood test- glycemia.
|
From baseline to 12 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Bruno FALISSARD, Pr, Paris
- Investigatore principale: Pierre-Michel LLORCA, Pr, Clermont-Ferrand
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NIS-NFR-SER-2012/1
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .